– Impressive safety and efficacy for solid cancer patients followed by global clinical study plan SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ — SN Bioscience Co., Ltd. (CEO Younghwan Park) announced the results of the phase 1 clinical study of SNB-101, a nanoparticle anti-cancer new…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.